Literature DB >> 6413884

Effect of mannitol on increased intracranial pressure.

C P McGraw, G Howard.   

Abstract

We studied 61 patients with a closed head injury and increased intracranial pressure (ICP). The ICP was monitored continuously, concomitant with the administration of 20% mannitol. If the ICP remained higher than 25 mm Hg for 10 minutes or more, the patient was included in the study. Analysis of monitoring records delineated four variables that were related to the response of ICP to mannitol: (a) the level of ICP 1 hour before mannitol was administered, (b) the level of ICP when mannitol was administered, (c) the amount of mannitol that was administered immediately before the resulting changes in ICP were measured, and (d) the cumulative amount of mannitol given over the 6 hours before the most recent mannitol dosage was administered. The level of the ICP measurements and the cumulative amount of preceding doses of mannitol influenced the response of ICP to mannitol more than did the size of the dose of mannitol. These findings imply that: (a) the initial administration of more mannitol than is absolutely needed may lead to larger doses being required to control ICP and (b) for that reason, mannitol given on a gram/kilogram, an hourly, or a serum osmolarity basis to control increased ICP has negative long term effects because more mannitol may be required to decrease ICP when an excessive amount of it has been given previously.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413884     DOI: 10.1227/00006123-198309000-00009

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  18 in total

Review 1.  Neurocritical care and traumatic brain injury.

Authors:  R C Tasker
Journal:  Indian J Pediatr       Date:  2001-03       Impact factor: 1.967

Review 2.  Osmotic therapy: fact and fiction.

Authors:  Michael N Diringer; Allyson R Zazulia
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Effect of Hyperosmolar Therapy on Outcome Following Spontaneous Intracerebral Hemorrhage: Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) Study.

Authors:  Manan Shah; Lee Birnbaum; Jennifer Rasmussen; Padmini Sekar; Charles J Moomaw; Jennifer Osborne; Anastasia Vashkevich; Daniel Woo
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-01-03       Impact factor: 2.136

Review 4.  The use of targeted temperature management for elevated intracranial pressure.

Authors:  Jesse J Corry
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

Review 5.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

6.  Mannitol enhances delivery of marrow stromal cells to the brain after experimental intracerebral hemorrhage.

Authors:  Donald M Seyfried; Yuxia Han; Dongmei Yang; Jennifer Ding; Smita Savant-Bhonsale; Mohammad S Shukairy; Michael Chopp
Journal:  Brain Res       Date:  2008-06-10       Impact factor: 3.252

7.  Formula for use of mannitol in patients with intracerebral haemorrhage and high intracranial pressure.

Authors:  Ge Tan; Jiying Zhou; Dongli Yuan; Shanquan Sun
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

8.  Use of mannitol during neurosurgery: interpatient variability in the plasma and CSF levels.

Authors:  P Anderson; L Boréus; E Gordon; M Lagerkranser; A Rudehill; C Lindquist; G Ohman
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Variable change in renal function by hypertonic saline.

Authors:  Jesse J Corry; Panayiotis Varelas; Tamer Abdelhak; Stacey Morris; Marlisa Hawley; Allison Hawkins; Michelle Jankowski
Journal:  World J Crit Care Med       Date:  2014-05-04

10.  Head-injured adult patients with GCS of 3 on admission--who have a chance to survive?

Authors:  Z Kotwica; J K Jakubowski
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.